Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.

United Therapeutics (NASDAQ:UTHR) surged 14% on Monday after the company reported positive Phase 3 results for nebulized Tyvaso in treating idiopathic pulmonary fibrosis, a chronic lung disease that ...

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis. A new systematic review and meta-analysis suggests ...

Plus, when to see a doctor.

AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and fibrotic diseases, today announced the dosing of the first patients in the ...

Common symptoms like shortness of breath or a lingering cough may seem harmless, but when they persist, they could point to ...

Shelley Harris, an Oak Park Public Library employee, hosted a healing circle event for people to share their experiences and ...

A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...

Cautionary Language Concerning Forward-Looking Statements ...

Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has ...